Treatment with venlafaxine in six cases of children with narcolepsy and with cataplexy and hypnagogic hallucinations

Journal of Child and Adolescent Psychopharmacology

Volumn 19, Issue 2, 2009, Pages 197-201

  Møller, Lene Ruge ^a   Østergaard, John R ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

CITALOPRAM; METHYLPHENIDATE; MODAFINIL; VENLAFAXINE;

AGGRESSION; ANAMNESIS; ARTICLE; CATAPLEXY; CHILD; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DEPRESSION; DISEASE SEVERITY; DRUG DOSE INCREASE; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; EMOTIONAL DISORDER; FEMALE; HUMAN; HYPERTENSION; HYPNAGOGIC HALLUCINATION; LOADING DRUG DOSE; MALE; MORNING DOSAGE; NARCOLEPSY; NAUSEA; NOCTURNAL SLEEP DISORDER; SCHOOL CHILD; SIDE EFFECT; SLEEP DISORDER; SUICIDAL IDEATION;

CATAPLEXY; CHILD; CYCLOHEXANOLS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HALLUCINATIONS; HUMANS; MALE; NARCOLEPSY; SEROTONIN UPTAKE INHIBITORS;

EID: 65249166541     PISSN: 10445463     EISSN: None     Source Type: Journal    
DOI: 10.1089/cap.2008.036     Document Type: Article

References (27)

1. Abad VC, Guilleminault C: Emerging drugs for narcolepsy. Expert Opin Emerg Drugs 9:281-291, 2004.
2. Banerjee D, Vitiello MV, Grunstein RR: Pharmacotherapy for excessive daytime sleepiness. Sleep Med Rev 8:339-354, 2004.
3. Black J, Houghton WC: Sodium oxybate improves excessive daytime sleepiness in narcolepsy. Sleep 29:939-946, 2006.
4. Challamel MJ, Mazzola ME, Nevsimalova S, Cannard C, Louis J, Revol M: Narcolepsy in children. Sleep 17:S17-S20, 1994.
5. Chemelli RM, Willie JT, Sinton CM, Elmquist JK, Scammell T, Lee C, Richardson JA, Williams SC, Xiong Y, Kisanuki Y, Fitch TE, Nakazato M, Hammer RE, Saper CB, Yanagisawa M: Narcolepsy in orexin knockout mice: Molecular genetics of sleep regulation. Cell 98:437-451, 1999.
6. Dahl RE, Holttum J, Trubnick L: A clinical picture of child and adolescent narcolepsy. J Am Acad Child Adolesc Psychiatry 33:834-841, 1994.
7. Guilleminault C, Pelayo R: Narcolepsy in prepubertal children. Ann Neurol 43:135-142, 1998.
8. Houghton WC, Scammell TE, Thorpy M: Pharmacotherapy for cataplexy. Sleep Med Rev 8:355-366, 2004.
9. Izzi F, Placidi F, Marciani MG, Zannino S, Torelli F, Corte F, Pisani LR, Romigi A: Effective treatment of narcolepsycataplexy with duloxetine: A report of three cases. Sleep Med 10:153-154, 2008.
10. Kotagal S, Hartse KM, Walsh JK: Characteristics of narcolepsy in preteenaged children. Pediatrics 85:205-209, 1990.
11. Lin L, Faraco J, Li R, Kadotani H, Rogers W, Lin X, Qiu X, de Jong PJ, Nishino S, Mignot E: The sleep disorder canine narcolepsy is caused by a mutation in the hypocretin (orexin) receptor 2 gene. Cell 98:365-376, 1999.
12. Mignot E: An update on the pharmacotherapy of excessive daytime sleepiness and cataplexy. Sleep Med Rev 8:333-338, 2004.
13. Mignot E, Nishino S: Emerging therapies in narcolepsycataplexy. Sleep 28:754-763, 2005.
14. Mignot E, Renaud A, Nishino S, Arrigoni J, Guilleminault C, Dement WC: Canine cataplexy is preferentially controlled by adrenergic mechanisms: Evidence using monoamine selective uptake inhibitors and release enhancers. Psychopharmacology (Berl) 113:76-82, 1993.
15. Mines D, Hill D, Yu H, Novelli L: Prevalence of risk factors for suicide in patients prescribed venlafaxine, fluoxetine, and citalopram. Pharmacoepidemiol Drug Saf 14:367-372, 2005.
16. Møller LR, Østergaard JR: [Narcolepsy in children - an overlooked diagnosis]. Ugeskr Laeger 167:2390-2393, 2005.
17. Nishino S, Mignot E: Pharmacological aspects of human and canine narcolepsy. Prog Neurobiol 52:27-78, 1997.
18. Nishino S, Arrigoni J, Shelton J, Dement WC, Mignot E: Desmethyl metabolites of serotonergic uptake inhibitors are more potent for suppressing canine cataplexy than their parent compounds. Sleep 16:706-712, 1993.
19. Overeem S, Mignot E, van Dijk JG, Lammers GJ: Narcolepsy: Clinical features, new pathophysiologic insights, and future perspectives. J Clin Neurophysiol 18:78-105, 2001.
20. Ripley B, Fujiki N, Okura M, Mignot E, Nishino S: Hypocretin levels in sporadic and familial cases of canine narcolepsy. Neurobiol Dis 8:525-534, 2001.
21. Rubino A, Roskell N, Tennis P, Mines D, Weich S, Andrews E: Risk of suicide during treatment with venlafaxine, citalopram, fluoxetine, and dothiepin: Retrospective cohort study. BMJ 334:242, 2007.
22. Stores G: Recognition and management of narcolepsy. Arch Dis Child 81:519-524, 1999.
23. Stores G, Montgomery P, Wiggs L: The psychosocial problems of children with narcolepsy and those with excessive daytime sleepiness of uncertain origin. Pediatrics 118:e1116-e1123, 2006.
24. Thirumalai SS, Shubin RA: The use of citalopram in resistant cataplexy. Sleep Med 1:313-316, 2000.
25. Thorpy M: Current concepts in the etiology, diagnosis and treatment of narcolepsy. Sleep Med 2:5-17, 2001.
26. Whittington CJ, Kendall T, Fonagy P, Cottrell D, Cotgrove A, Boddington E: Selective serotonin reuptake inhibitors in childhood depression: Systematic review of published versus unpublished data. Lancet 363:1341-1345, 2004.
27. Wise MS: Childhood narcolepsy. Neurology 50:S37-S42, 1998.